|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.68 CNY | -0.60% |
|
+7.35% | +19.31% |
| 04-29 | Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-16 | Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets | MT |
Shanghai Shyndec Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 6,444.53 million compared to CNY 6,387.02 million a year ago. Net income was CNY 344.94 million compared to CNY 224.85 million a year ago.
Basic earnings per share from continuing operations was CNY 0.286 compared to CNY 0.2189 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +19.31% | 2.17B | |
| +7.91% | 72.81B | |
| -10.56% | 5.13B | |
| +58.79% | 4.99B | |
| +4.07% | 3.9B | |
| -16.90% | 2.48B | |
| +20.84% | 2.42B | |
| -26.13% | 2.32B | |
| -0.50% | 1.64B | |
| +0.07% | 1.59B |
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. 